COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein S1 D614G mutant (S1-D614G,C-HisTag)

Order information

Package	Catalog No.	Price(In USD)	Qty (Quantity)	Sum(In USD)
1mg	GMP-V-2019nCoV-Smu-001-1mg	5990
10mg	GMP-V-2019nCoV-Smu-001-10mg	38790
100mg	GMP-V-2019nCoV-Smu-001-100mg	258000
≥100mg	GMP-V-2019nCoV-Smu-001-xmg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Accession Number	QHD43415.1
Expression platform	2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
Isotypes	Mamamlian (human cell)
Tag	C-His
Products description	Recombinant 2019-nCoV(SARS-CoV-2)e Spike Protein S1 domain with D614G mutant was expressed in mammanlian cell (human cells)expression system. The target gene encoding Gln14-Arg685(D614G) was expressed with HIS tag at the C-terminus.
Bioactivity validation	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
Purity	Purity: ≥95% (SDS-PAGE)
Application	Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass	76kDa
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein S1 D614G mutant (S1-D614G,C-HisTag).

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-20 vaccines and therapeutic antibodies. Validated in functional ELISA, other immunoassays, the antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. The D614G mutation in Spike S1 domain is proved to be a most important and popular mutant variant in Coronavirus SARS-CoV2.